Prof. Eric Raymond Oncologie Medicale

16 Seguidores

Prof Eric Raymond is consultant, head of medical oncology at the Paris Saint-Joseph Hospital. Eric Raymond is board certified MD specialized in medical oncology and obtained a PhD degree in cellular and molecular biology, working on preclinical mechanisms of action and combinations of several novel anticancer drugs. He has been appointed as Chef de Clinique in Paris 6 Curie University with Prof. A. de Gramont for two years before undertaking a 2 year post-doctoral fellowship with Daniel D. Von Hoff at the Cancer Therapy and Research Center and Institute for Drug Development at the University of Texas in San Antonio, USA, Then, Eric Raymond undertook clinical and translational research in...

cancer immunotherapy hepatocellular carcinoma antiangiogenic agent targeted therapy new drugs resistance to anti-angiogenic drug neuroendocrine tumors hepatocarcinoma covid-19 targeted agents sunitinib vegfr tgf-beta drug development oncologie oncology pancreatic adenocarcinoma cancer du colon angiogenesis pancreas resistance to chemotherapy resistance to immunotherapy pnet targeted agent hépatocarcinome new drug tepotinib c-met pandemic oncologist covid novel targets medical oncology octobre rose lingerie cancer du sein car-t cell hcc chirurgie immunotherapie chimiotherapie pdl1 pd1 pdgfr bevacizumab tumeur neuroendocrine cell signaling squamous cell carcinoma anal cancer tissue slicer transgenic mice leukemia resistance to radiotherapy mtor chemotherapy liver metastases clinical trial phase 1 second line hgf combination therapy sorafenib new target fgfr4 healthcare moratlity outbreak cancer mortality hospital managment cancer therapy prevention primary liver malignancy liver cancer yvon taillandier relations franco chinoises maladies carciovasculaires cancérologie hématologie research genetics inca acreditation inssurance microenvironment biomarkers novel drugs vegfr inhibitors tgf-beta inhibitor met inhibitor brca treatment of pancreatic cancer parp inhibitor tumor resistance hypoxia hif1-alpha patient selection pharmacodynamic pharmacokinetic methodology pf-03084014 head & neck cancer cancer research cell lines human model notch murine model danse smoothies recettes coiffure maquillage saint-joseph sophrologie manucure conditional survival cancer breast cancer survival risk management biopsy cholangiocarcinoma pricing medicine toxicity safety solid tumor hormonothérapie intervention chirurgicale therapie ciblee humanized hospital rehabilitation prehabilitation hormonotherapy interventional radiology surgery fgf19 met-inhibitor nab-paclitaxel folfirinox locally advanced borderline operable gemcitabine multidisciplinarité chimioembolisation carcinose cancer du rectum intrapéritonéale pdgf vegf bio marqueurs sanguins cancer du foie cancer du rein immunotherpy genetic background vaccination hpv18 hpv16 imaging immunodeficiency human immunodeficiency virus prognostic factor pet-scaning hiv first line suntinib pancreatic phase 4 ex vivo models mouse experiments antiangiogenics preclinical models biotechnoligy transcription nut otx-015 lymphoma jq1 breast cancer neuroblastoma prostate cancer bromodomain inhibitor otx015 nmc transcription reader bromodomain tivantinib crizotinib resistance to targeted agent her3 her2 precision medicine lanreotide everolimus anti-oncogene men1 somatuline net checkpoint inhibitor signaling inhibitors vhl endocrine malignancies somatostatin receptor ssa multimodality therapy liver-directed therapy galunisertib small molecule translational research ipilimumab galunisetib innovative therapy nivolumab blu-554 regorafenib

Ver mais